Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor agonist.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

Antimicrobials, vaccines, anti-inflammatories linked to reduced risk for Alzheimer disease and dementia; antipsychotics and diabetes drugs tied to higher risk ...

Fractures in nonambulatory children that are not consistent with history or for which no history of injury is given are concerning for abuse ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

HealthDay News — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

The Food and Drug Administration (FDA) has approved 2 additional vial sizes of Niktimvo ™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.

In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.